Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Revolution Medicines, Inc.
- Study ID
- NCT07491445
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Pancreatic Adenocarcinoma
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Adenosquamous Carcinoma
- Pancreatic Cancer
- Pancreatic Cancer Metastatic
- Pancreatic Ductal Adenocarcinoma (PDAC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- daraxonrasib — DRUGoral tablets
- gemcitabine — DRUGintravenous (IV) infusion
- nab-paclitaxel — DRUGIV infusion
Study Details
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Key Dates
- First listed
- Mar 24, 2026
- Start date
- Mar 9, 2026
- Status verified
- Jul 2026
- Primary completion
- Jun 30, 2028
- Completion
- Mar 31, 2029
Study Design
- Enrollment
- 900 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A: daraxonrasibstudy drug
- Experimental: Arm B: daraxonrasib + gemcitabine and nab-paclitaxelstudy drug in combination with chemotherapy
- Active Comparator: Arm C: gemcitabine and nab-paclitaxelSOC chemotherapy
Primary Outcome Measure
Progression free survival (PFS) [ Time Frame: Up to approximately 2 years ]
Central Contacts
- Revolution Medicines Study Director1-844-2-REVMED
Locations (13)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Honor Health Research Institute | Scottsdale | Arizona | 85258 | Carolina Robertson |
| H Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21287 | |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | |
| Comprehensive Cancer Centers of Nevada | Henderson | Nevada | 89052 | |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | |
| University of Cincinnati Cancer Center | Cincinnati | Ohio | 45219 | |
| Taylor Cancer Research Center | Maumee | Ohio | 43537 | |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | |
| SCRI - Texas Oncology Dallas | Dallas | Texas | 95246 | |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Kamisha Jernigan |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | |
| Virginia Mason Medical Center | Seattle | Washington | 98101 |
Find similar trials in Scottsdale, AZ
By condition
By specialty
By research site
Honor Health Research Institute· Scottsdale, AZH Lee Moffitt Cancer Center and Research Institute· Tampa, FLJohns Hopkins Sidney Kimmel Comprehensive Cancer Center· Baltimore, MDDana-Farber Cancer Institute· Boston, MAComprehensive Cancer Centers of Nevada· Henderson, NVMemorial Sloan Kettering Cancer Center· New York, NY
Related Studies
- Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersRecruiting · Mayo Clinic · Phoenix, Arizona
- Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer PatientsRecruiting · Vanderbilt University Medical Center · Nashville, Tennessee
- PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic DiseaseRecruiting · Columbia University · New York, New York
- Pancreatic Cancer GeneticsRecruiting · Columbia University · New York, New York